98%
921
2 minutes
20
Background: In Modern dentistry, the implant is the most popular and desirable management of tooth loss. Traditionally two stage (submerged) or one-stage (non-submerged) system has been added by many investigators. In the present study we evaluated the crestal bone loss during osseointegration phase among the three groups (i.e. submerged implants, non-submerged implants with anatomical healing abutment and non- submerged implants with esthetic healing abutment).
Material And Methods: 10 subjects with 30 implants, were enrolled in the study. Subjects were randomized in three groups i.e., group 1 submerged (n=10), group 2 non-submerged with anatomical healing abutment (=10), group 3 non submerged with esthetic healing abutments (=10). Intraoral periapical radiograph (IOPA), IMAGE J software and CBCT were used to evaluate the crestal bone loss around each implant at baseline, 1 and 3 months after implant placement.
Results: Crestal bone loss at the end of the 3months (osseointegration phase) was lowest in the submerged group (0.18+-0.06mm) followed by non-submerged esthetic group (0.21+-0.03mm) but it was statistically insignificant. Maximum amount of bone loss was observed in non-submerged anatomical abutment group (0.34+-0.03mm) which was highly significant.
Conclusion: It can be concluded that submerged implants technique is a better option in comparison to non-submerged implant technique in terms of radiographical performance during initial phases of osseointegration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371283 | PMC |
http://dx.doi.org/10.4103/njms.njms_116_22 | DOI Listing |
Calcif Tissue Int
September 2025
FirmoLab, Fondazione F.I.R.M.O. Onlus and Stabilimento Chimico Farmaceutico Militare (SCFM), 50141, Florence, Italy.
X-linked hypophosphatemia (XLH) is a rare and progressive disease, due to inactivating mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene. These pathogenic variants result in elevated circulating levels of fibroblast growth factor 23 (FGF23), responsible for the main clinical manifestations of XLH, such as hypophosphatemia, skeletal deformities, and mineralization defects. However, XLH also involves muscular disorders (muscle weakness, pain, reduced muscle density, peak strength, and power).
View Article and Find Full Text PDFActa Ortop Mex
September 2025
Servicio de Ortopedia y Traumatología, Hospital de San Rafael, Hospitales Pascual. Cádiz, España.
Introduction: anatomical deformities such as developmental dysplasia of the hip (DDH) and Perthes disease represent a challenge for reconstruction. The use of 3D-printed models can be helpful for assessing the deformity, bone mass, implant size, and orientation.
Objectives: to prospectively evaluate the outcomes of 3D simulation in primary total hip arthroplasty.
J Neurol Surg A Cent Eur Neurosurg
September 2025
Neurosurgery, University of Tsukuba Institute of Medicine, Tsukuba, Japan.
Background: Intracranial solitary fibrous tumors (SFTs) are rare mesenchymal tumors often presenting with dural-based lesions. These tumors can exhibit aggressive characteristics with high recurrence rates and extracranial metastasis. While SFTs occasionally invade venous sinuses, cases where the tumor arises within the venous sinus are rare.
View Article and Find Full Text PDFSci Total Environ
September 2025
Department of Orthopedics and Traumatology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan Province, China. Electronic address:
The objective of this research was to use a network toxicology approach to examine the possible toxicity of the cigarette toxicants nicotine and coal tar that cause osteoporosis (OP) as well as its molecular processes. We determined the primary chemical structures and 128 targets of action of tar and nicotine using the Swiss Target Prediction, NP-MRD, and PubChem databases. We discovered that genes including DNAJB1, CCDC8, LINC00888, ATP6V1G1, MPV17L2, PPCS, and TACC1 had a disease prognostic guiding value by LASSO analysis and differential analysis of GEO microarray data.
View Article and Find Full Text PDFIntroduction: The ADHEAR is a non-surgical Bone Conduction Device (BCD) that makes use of an adhesive adapter. While clinical trials have demonstrated its efficacy with regards to audiological performance, safety and compliance, data on real-world paediatric cohorts is scarce.
Methods: This retrospective cohort study analysed data from paediatric patients fitted with ADHEAR at a tertiary centre between January 2017 and September 2024.